MA33083B1 - Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament - Google Patents

Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament

Info

Publication number
MA33083B1
MA33083B1 MA33613A MA33613A MA33083B1 MA 33083 B1 MA33083 B1 MA 33083B1 MA 33613 A MA33613 A MA 33613A MA 33613 A MA33613 A MA 33613A MA 33083 B1 MA33083 B1 MA 33083B1
Authority
MA
Morocco
Prior art keywords
medicine
compounds
dietary supplement
containing sulfur
fats containing
Prior art date
Application number
MA33613A
Other languages
Arabic (ar)
English (en)
Inventor
Anne Kristin Holmeide
Ragnar Hovland
Morten Braendvang
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33083(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of MA33083B1 publication Critical patent/MA33083B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/04—Sulfinic acids; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/55—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR DES COMPOSÉS LIPIDIQUES SELON LA FORMULE GÉNÉRALE (I) : (I) DANS LAQUELLE R1 EST CHOISI PARMI UN ALKYLE EN C10-C22, UN ALCÉNYLE EN C10-C22 AYANT 1 À 6 DOUBLES LIAISONS ET UN ALCYNYLE EN C10-C22 AYANT 1 À 6 TRIPLES LIAISONS; R2 ET R3 SONT IDENTIQUES OU DIFFÉRENTS ET PEUVENT ÊTRE CHOISIS DANS UN GROUPE DE DIFFÉRENTS SUBSTITUANTS; Y EST CHOISI PARMI SULFURE, SULFOXYDE ET SULFONE; ET X REPRÉSENTE UN ACIDE CARBOXYLIQUE OU UN DÉRIVÉ DE CELUI-CI, UN ESTER CARBOXYLIQUE, UN ANHYDRE CARBOXYLIQUE OU UN CARBOXAMIDE; OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, COMPLEXE OU SOLVATE DE CEUX-CI. L'INVENTION PORTE ÉGALEMENT SUR DES COMPOSITIONS PHARMACEUTIQUES ET SUR DES COMPOSITIONS LIPIDIQUES COMPRENANT DE TELS COMPOSÉS, ET SUR DE TELS COMPOSÉS POUR UTILISATION EN TANT QUE MÉDICAMENTS OU POUR UNE UTILISATION EN THÉRAPIE, EN PARTICULIER POUR LE TRAITEMENT DE MALADIES RELATIVES AU DOMAINE DES MALADIES CARDIOVASCULAIRES, MÉTABOLIQUES ET INFLAMMATOIRES.
MA33613A 2008-07-15 2009-07-13 Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament MA33083B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8080408P 2008-07-15 2008-07-15
EP08160450A EP2147910A1 (fr) 2008-07-15 2008-07-15 Nouveaux composés lipidiques
PCT/NO2009/000262 WO2010008299A1 (fr) 2008-07-15 2009-07-13 Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament

Publications (1)

Publication Number Publication Date
MA33083B1 true MA33083B1 (fr) 2012-03-01

Family

ID=40419454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33613A MA33083B1 (fr) 2008-07-15 2009-07-13 Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament

Country Status (29)

Country Link
US (3) US8759558B2 (fr)
EP (2) EP2147910A1 (fr)
JP (1) JP5628164B2 (fr)
KR (2) KR20110031497A (fr)
CN (1) CN102159200B (fr)
AU (1) AU2009271791B2 (fr)
BR (1) BRPI0916456B8 (fr)
CA (1) CA2730958C (fr)
CL (2) CL2011000090A1 (fr)
CO (1) CO6341548A2 (fr)
DK (1) DK2313090T3 (fr)
EA (1) EA022593B1 (fr)
ES (1) ES2573977T3 (fr)
HK (1) HK1161078A1 (fr)
HR (1) HRP20160557T1 (fr)
HU (1) HUE029195T2 (fr)
IL (1) IL210673A (fr)
IN (1) IN2011CH01039A (fr)
MA (1) MA33083B1 (fr)
MX (1) MX2011000556A (fr)
MY (1) MY153620A (fr)
NZ (2) NZ590645A (fr)
PH (1) PH12011500113A1 (fr)
PL (1) PL2313090T3 (fr)
SG (1) SG192525A1 (fr)
UA (1) UA109252C2 (fr)
VN (1) VN28144A1 (fr)
WO (1) WO2010008299A1 (fr)
ZA (1) ZA201100666B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (fr) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Composés lipidiques à utiliser dans des produits cosmétiques, en tant que suppléments alimentaires ou en tant que médicaments
EP2147910A1 (fr) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Nouveaux composés lipidiques
PT2427415T (pt) * 2009-05-08 2019-05-31 Basf As Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória
RS62335B1 (sr) 2010-05-21 2021-10-29 Coors Brewing Co Pripremanje kiselina iz hmelja i njihovih derivata
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2612669A4 (fr) 2010-08-31 2014-05-14 Snu R&Db Foundation Utilisation de la reprogrammation f tale d'un agoniste des ppar
GB201014633D0 (en) 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
UA111475C2 (uk) * 2010-11-05 2016-05-10 Пронова Байофарма Нордж Ас Способи лікування із застосуванням ліпідних сполук
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
KR101390589B1 (ko) * 2012-05-30 2014-04-30 가천대학교 산학협력단 다이아민을 포함하는 당뇨병의 예방 또는 치료용 조성물
EP2961384B1 (fr) 2013-02-28 2019-08-28 Basf As Composition comprenant un composé lipidique, un triglycéride et un tensioactif, et procédés d'utilisation associés
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201501144D0 (en) * 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
CA2983377C (fr) * 2015-04-28 2023-08-29 Pronova Biopharma Norge As Utilisation d'acides gras structurellement ameliores contenant du soufre pour prevenir et/ou traiter la steatose hepatique non alcoolique
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
JP2019529555A (ja) 2016-09-21 2019-10-17 アヴェクシン エーエス 医薬組成物
EP3661600A4 (fr) 2017-10-23 2021-08-11 Epitracker, Inc. Analogues d'acides gras et leur utilisation dans le traitement des états liés au syndrome métabolique
WO2019111048A1 (fr) 2017-12-06 2019-06-13 Basf As Dérivés d'acide gras pour le traitement de la stéatohépatite non alcoolique
WO2019222254A1 (fr) * 2018-05-16 2019-11-21 Epitracker, Inc. Compositions et procédés de diagnostic et de traitement d'états liés au vieillissement
CA3099482A1 (fr) 2018-05-23 2019-11-28 Epitracker, Inc. Compositions et methodes pour le diagnostic et le traitement d'affections liees a la longevite et a la qualite du vieillissement
CA3101041A1 (fr) * 2018-05-23 2019-11-28 Northsea Therapeutics B.V. Acides gras structurellement modifies pour ameliorer la regulation glycemique et traiter une maladie intestinale inflammatoire
WO2020236009A1 (fr) * 2019-05-20 2020-11-26 T Omega As Composés d'acides gras pour la prévention et le traitement d'un dysfonctionnement mitochondrial
JP2023506398A (ja) * 2019-12-19 2023-02-16 リミナル・バイオサイエンシーズ・リミテッド シクロアルキル含有カルボン酸及びそれらの使用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909554A (en) * 1956-07-23 1959-10-20 Monsanto Chemicals Process for the manufacture of (alkylmercapto) alkyl sulfates
GB1038723A (fr) 1962-03-26
JPS4839001B1 (fr) * 1970-11-09 1973-11-21
US4040781A (en) * 1974-06-06 1977-08-09 Lever Brothers Company Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same
US4032564A (en) * 1974-09-09 1977-06-28 Zoecon Corporation Esters of cyclopropylalkanols
GB1523276A (en) 1974-09-20 1978-08-31 Lafon Labor Sulphur-containing amino compounds
US4009211A (en) * 1975-07-29 1977-02-22 Gulf Research & Development Company Beta,beta-dialkylethylmercaptoethoxylate as new compounds
US4209410A (en) * 1976-04-28 1980-06-24 Phillips Petroleum Company Lubricants
EP0002007B1 (fr) 1977-11-11 1982-07-28 Ciba-Geigy Ag Dérivés d'esters de diacides de pyridine, leurs mélanges avec des agents stabilisants métalliques et leur emploi comme agents stabilisants de thermoplastes chlorés
JPS5570841A (en) * 1978-11-24 1980-05-28 Konishiroku Photo Ind Co Ltd Forming method of dye image
US4368190A (en) * 1980-04-17 1983-01-11 Merck & Co., Inc. Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
EP0050327B1 (fr) 1980-10-21 1984-06-20 Roche Diagnostics GmbH Phospholipides contenant du soufre, leur procédé de préparation et médicaments contenant ces composés
US4411808A (en) * 1982-08-04 1983-10-25 Exxon Research & Engineering Co. Multifunctional additive for power transmission shift fluids
US4775223A (en) 1984-09-20 1988-10-04 Canon Kabushiki Kaisha Lactic acid derivative, liquid crystal composition containing same and liquid crystal device
CA2010000A1 (fr) * 1989-04-07 1990-10-07 Paul B. Merkel Materiau d'enregistrement photographique contenant un coupleur de formation de colorant bleu-vert
JPH0451149A (ja) * 1990-06-19 1992-02-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
FR2663928B1 (fr) 1990-06-27 1994-04-08 Norsolor Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres.
JPH0543529A (ja) * 1991-08-10 1993-02-23 Taisho Pharmaceut Co Ltd アルカンアミドアンモニウム化合物
US5328952A (en) * 1992-02-14 1994-07-12 Rohm And Haas Company Multi-stage polymer latex cement modifier and process of making
JP2755279B2 (ja) * 1992-03-19 1998-05-20 三井化学株式会社 熱可塑性樹脂組成物およびその成形体
JP2793458B2 (ja) * 1992-03-19 1998-09-03 三井化学株式会社 コネクター用ポリアミド系樹脂組成物およびコネクター
CA2164717C (fr) * 1993-06-10 2009-10-20 Louis S. Kucera Methode de lutte contre une infection due au virus de l'hepatite b
JP3110918B2 (ja) * 1993-06-18 2000-11-20 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
DK70295A (da) * 1994-07-01 1996-01-02 Ciba Geigy Ag Titan- og zirkonium-komplekser af carboxylsyrer som korrosionsinhibitorer
KR100463709B1 (ko) * 1994-10-13 2005-08-04 위민스 앤드 칠드런스 호스피털 애드레이드 변형된불포화지방산
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
FR2741619B1 (fr) * 1995-11-28 1998-02-13 Pf Medicament Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
GB2328155B (en) 1996-04-12 2000-08-02 Peptide Technology Pty Limited Methods of treating immunopathologies using polyunsaturated fattyacids
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
WO1999058120A1 (fr) * 1998-05-08 1999-11-18 Rolf Berge Utilisation d'analogues d'acides gras non beta-oxydables pour traiter les etats lies au syndrome x
FR2786187B1 (fr) * 1998-11-19 2001-11-09 Univ Paris Curie Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations
FR2792312B1 (fr) * 1999-04-15 2001-06-08 Oreal Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation
AR018472A1 (es) 1999-06-01 2001-11-14 Procter & Gamble Compuesto, composicion y metodo para el tratamiento de la perdida de cabello
US6723717B1 (en) * 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
FR2828487B1 (fr) 2001-08-09 2005-05-27 Genfit S A Nouveaux composes derives d'acides gras, preparation et utilisations
US20030147814A1 (en) * 2001-12-21 2003-08-07 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
GB2383355A (en) * 2001-12-22 2003-06-25 Schlumberger Holdings An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant
BR0307265B1 (pt) * 2002-01-31 2012-11-27 composição substancialmente isenta de solvente, emulsão concentrada, e processo para tratamento e conferência de repelência à água a materiais fibrosos, couro, peles e têxteis.
AU2003251518B2 (en) * 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
EP1515978A1 (fr) 2002-06-20 2005-03-23 IC Vec Limited Derives phospholipidiques contenant du soufre
FR2845991B1 (fr) * 2002-10-16 2005-02-04 Pf Medicament Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
WO2004076404A1 (fr) * 2003-02-28 2004-09-10 Kaneka Corpration Procedes pour la production de composes optiquement actifs comportant des substituants en position 2
DE10326303A1 (de) * 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
JP2007522118A (ja) 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
JP4563114B2 (ja) 2004-08-30 2010-10-13 出光興産株式会社 潤滑剤用添加剤
CA2599673A1 (fr) 2005-03-08 2006-09-14 Reinhold Oehrlein Nanoparticules d'oxyde metallique revetues par des phosphonates specifiques
WO2006117668A1 (fr) * 2005-05-04 2006-11-09 Pronova Biopharma Norge As Analogues d'acides gras, autrement dit derives dha utilises comme medicament
ES2391305T3 (es) 2006-04-12 2012-11-23 Unilever N.V. Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
EP1849449A1 (fr) * 2006-04-26 2007-10-31 3M Innovative Properties Company Composition contenant de la charge et precédé de fabrication et d'utilisation correspondants
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
BRPI0713096A2 (pt) * 2006-05-09 2012-10-16 Hemaquest Pharmaceuticals Inc métodos para tratar distúrbios sangüìneos
KR101438177B1 (ko) * 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
WO2008053340A1 (fr) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As Produit de combinaison comprenant au moins un lipide substitué en position alpha et au moins un agent hypoglycémique
CN101225064A (zh) * 2007-01-19 2008-07-23 上海汇瑞生物科技有限公司 一种制备β-硫杂-α-烷基脂肪酸的新方法
DE102007017179A1 (de) 2007-04-12 2008-10-23 Clariant International Ltd. Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation
WO2009061208A1 (fr) * 2007-11-09 2009-05-14 Pronova Biopharma Norge As Composés lipidiques à utiliser dans des produits cosmétiques, en tant que suppléments alimentaires ou en tant que médicaments
WO2009149496A1 (fr) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Traitement du diabète, de ses complications et de troubles associés
FR2933006B1 (fr) 2008-06-27 2010-08-20 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante
EP2813486B1 (fr) 2008-07-08 2017-10-25 Catabasis Pharmaceuticals, Inc. Salicylates acétylés d'acides gras et leurs utilisations
EP2147910A1 (fr) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Nouveaux composés lipidiques
PT2427415T (pt) 2009-05-08 2019-05-31 Basf As Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória
DK2473045T3 (en) * 2009-09-01 2016-12-12 Catabasis Pharmaceuticals Inc Niacin-FATTY ACID CONJUGATES AND THEIR USES
TW201138832A (en) 2010-01-20 2011-11-16 Pronova Biopharma Norge As Salicylate fatty acid derivatives
UA111475C2 (uk) 2010-11-05 2016-05-10 Пронова Байофарма Нордж Ас Способи лікування із застосуванням ліпідних сполук
WO2012115695A1 (fr) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Conjugués de bis-acides gras et leurs utilisations
WO2013016531A2 (fr) 2011-07-26 2013-01-31 Purdue Research Foundation Composés et méthodes de traitement d'une néoplasie ou d'un cancer

Also Published As

Publication number Publication date
IL210673A (en) 2015-02-26
HRP20160557T1 (hr) 2016-06-17
KR20110031497A (ko) 2011-03-28
EP2313090A4 (fr) 2012-01-18
HK1161078A1 (en) 2012-08-24
CA2730958A1 (fr) 2010-01-21
CL2018001111A1 (es) 2018-07-20
JP2011528350A (ja) 2011-11-17
CL2011000090A1 (es) 2012-03-30
US20170029368A1 (en) 2017-02-02
MY153620A (en) 2015-02-27
ES2573977T3 (es) 2016-06-13
AU2009271791A1 (en) 2010-01-21
EA022593B1 (ru) 2016-01-29
CN102159200A (zh) 2011-08-17
MX2011000556A (es) 2011-03-15
ZA201100666B (en) 2011-10-26
EP2313090B1 (fr) 2016-03-30
DK2313090T3 (en) 2016-06-13
EP2313090A1 (fr) 2011-04-27
EP2147910A1 (fr) 2010-01-27
EA201170193A1 (ru) 2011-08-30
NZ601501A (en) 2014-03-28
PH12011500113A1 (en) 2010-01-21
AU2009271791B2 (en) 2014-06-26
KR101901836B1 (ko) 2018-09-27
PL2313090T3 (pl) 2016-09-30
SG192525A1 (en) 2013-08-30
CO6341548A2 (es) 2011-11-21
VN28144A1 (en) 2011-12-26
KR20170093253A (ko) 2017-08-14
CN102159200B (zh) 2015-06-24
NZ590645A (en) 2012-08-31
BRPI0916456A2 (pt) 2018-06-12
JP5628164B2 (ja) 2014-11-19
HUE029195T2 (en) 2017-02-28
WO2010008299A1 (fr) 2010-01-21
UA109252C2 (uk) 2015-08-10
BRPI0916456B8 (pt) 2021-05-25
BRPI0916456B1 (pt) 2020-12-29
US20140316002A1 (en) 2014-10-23
IN2011CH01039A (fr) 2011-12-30
CA2730958C (fr) 2016-07-05
US8759558B2 (en) 2014-06-24
IL210673A0 (en) 2011-03-31
AU2009271791A2 (en) 2011-02-24
US20110190395A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
MA33083B1 (fr) Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament
JP6521967B2 (ja) 疾患の治療のためのｋｄｍ１ａ阻害剤
AU2016333963C1 (en) PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US7183285B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
EP3442948B1 (fr) Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
MX2009004336A (es) Lipidos omega-3 alfa-sustituidos que son activadores o moduladores del receptor activado por proliferadores de peroxisoma (ppar).
CA2576727C (fr) Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
EA201171371A1 (ru) Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями
US20070015779A1 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
Vega et al. The rise of proteostasis promoters
Chittiboyina et al. Design and synthesis of the first generation of dithiolane thiazolidinedione-and phenylacetic acid-based PPARγ agonists
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
Meirer et al. Synthesis and structure–activity relationship studies of novel dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase
EP1755607A2 (fr) Compositions et traitements pour l'inhibition de kinase et/ou de hmg-coa reductase
MA32798B1 (fr) Acides naphtylacétiques
US7163945B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
MA32108B1 (fr) Derives d'indazole
US7199126B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
MA27732A1 (fr) Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2019023448A1 (fr) Inhibiteurs de la nadph oxydase et leur utilisation
Toyama et al. Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317
US20050272770A1 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
JP2023523051A (ja) 脂質代謝関連疾患の予防又は治療用化合物
US20050282883A1 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase